Updated definitions of healthy ranges for serum alanine aminotransferase levels.
about
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver diseaseKASL clinical practice guidelines: management of chronic hepatitis BThe Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-AnalysisReview of nonalcoholic fatty liver disease in women with polycystic ovary syndromeAlanine aminotransferase-old biomarker and new concept: a reviewPersistent hypertransaminasemia in asymptomatic children: a stepwise approachNonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosisManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesAntiviral therapy for chronic hepatitis B in ChinaRevised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriersSerum hepatic enzyme activity and alcohol drinking status in relation to the prevalence of metabolic syndrome in the general Japanese populationNeck circumference, along with other anthropometric indices, has an independent and additional contribution in predicting fatty liver diseaseA Mechanistic Assessment of the Discordance between Normal Serum Alanine Aminotransferase Levels and Altered Liver Histology in Chronic Hepatitis BA new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis BDiagnosis, management, and treatment of hepatitis C: an updateCurrent role of transient elastography in the management of chronic hepatitis B patientsFibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Statins in liver disease: a molehill, an iceberg, or neither?Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels.Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.Predicting the presence of hepatitis B virus surface antigen in Chinese patients by pathology data mining.Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels.Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritisTo treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy.Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D surveyDiagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat.Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patientsMeaning of upper limit of normal range of post-load 1-h plasma glucose level defined by oral glucose tolerance test in Japanese subjects.Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy.Histological and clinical characteristics of patients with chronic hepatitis C and persistently normal alanine aminotransferase levelsLack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control studyNonalcoholic fatty liver disease: Diagnostic biomarkers.Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort studyFatty liver disease in children: eat now pay later.Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks
P2860
Q24800420-66CA940F-F320-40EA-A0EB-D36BEB5EEF60Q26752475-B2CB4083-083B-46DD-B1CB-41058262394DQ26777980-15F1F161-EB5A-4A18-BC8C-63626E95CC2BQ26828765-0FA57B0A-D8E7-4E9E-A7E9-05F4A96D1D68Q26828819-77CA0CC4-CCB9-4369-8BC0-B3D7FBEF4CC1Q26829883-27BC76CF-B98B-43A7-A16A-28CBB065DFC4Q26858875-68DDF730-4182-4B3A-ACF3-6AF3E4B879A8Q27000080-C278E48D-6EAF-4A7F-8EA6-93D5691954F1Q27006557-2EBEC49D-4F06-405B-8D27-A1D767FDEDDBQ28386713-EE25E081-CBBB-4069-AFD1-D7AC1D0D067EQ28538138-BC591194-AEF3-4175-A82F-1BE008DC322FQ28543519-1395F677-CF79-4CF3-8139-C78D3B123D16Q28546931-728F939E-58A4-4E7D-9215-D075C7142CEDQ28741501-1AEFB5BB-2AE1-49AA-8B5E-A0A7BE89066FQ29619682-0C616165-EA61-4B68-BCD9-7AA5B1C09F95Q30358894-375BDA41-0508-416A-B9EB-DE4CC8C6E339Q30383907-F465026A-5316-4540-9901-3565004B2EDBQ30391932-C03FD89A-EFE2-4F18-AE05-B4BBBB8E8D95Q30446668-344D21FB-9719-468B-A869-B3DF1F559F02Q30468484-0180A609-27B0-471F-8136-6F7A28DF3096Q30558355-8971FCCF-BC0C-4CE0-A3BE-A223ADF877DDQ30577903-BE5A117D-C501-4320-A630-DE1C8B1ED32FQ30589720-DFAD52E5-1D97-46FD-B395-19169D09ECD5Q30647985-BB6129D3-23BE-41EA-8BFF-C38DBB8A8DE9Q31126611-D4C53BED-22AF-48C8-8D11-C5089494E853Q33304235-09D87B78-4216-4467-AEFE-0B8018A2FF38Q33563893-80B351A2-8D5C-47B0-8D29-434E53AB9B01Q33575324-8568ABA5-21F1-4097-93EF-3EB8AA11D037Q33577715-3CF0A653-2EC7-4933-ADB4-B1075C1EC289Q33599576-5630EFFE-FECB-4C4D-847A-104E6AB9ACB2Q33607630-D671A8AB-E4E3-4089-B5ED-2DBE25D1BE54Q33609481-89E25027-077C-463D-8D10-5E79498E5EECQ33627245-20E9A211-E341-4DE9-98C1-4B3053FDCAEAQ33660486-62DA4FFC-48E8-41F9-B0F7-F6A1DF9F06DEQ33687762-2B9EE4F7-583F-4FC9-A740-2CDF6B0683B1Q33706254-D194C3DE-C98A-4263-86B9-8C670D1FF32CQ33709267-0ED36F41-6248-4062-9A65-5816113FA581Q33718945-410EB699-04AA-4721-AC2E-ADE650EE397AQ33718958-1FF008F0-1E5A-4D13-B66F-9F22536502B8Q33753902-93F8B21C-19DB-4863-8D3C-92031D072D21
P2860
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
@en
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
@nl
type
label
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
@en
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
@nl
prefLabel
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
@en
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
@nl
P2093
P1476
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
@en
P2093
Alberto Zanella
Dario Conte
Emanuela Del Vecchio
Emanuela Della Torre
Emanuela Taioli
Francesco Zanuso
Fulvio Mozzi
Girolamo Sirchia
Luciana Vianello
Massimo Colombo
P356
10.7326/0003-4819-137-1-200207020-00006
P407
P577
2002-07-01T00:00:00Z